Butler et al. discovered that ASH2L expression is significantly increased in a subset of AML patients carrying fms-related tyrosine kinase 3 (FLT3) mutations, and the ASH2L expression level is negatively associated with the overall survival rate [46]. This evidence concerns the gene ASH2L and acute myeloid leukemia.